Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

China Pharma Holdings, Inc. (CPHI)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.5895-0.0104 (-1.73%)
At close: 3:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5999
Open0.5959
Bid0.5701 x 900
Ask0.5895 x 800
Day's Range0.5760 - 0.6300
52 Week Range0.4200 - 1.6300
Volume184,733
Avg. Volume1,028,841
Market Cap25.69M
Beta (5Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.0670
Earnings DateMay 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • PR Newswire

    China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended September 30, 2021.

  • PR Newswire

    China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021.

  • PR Newswire

    China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Candesartan hypertension product passed key bioequivalence tests. The Company plans to use the results of the key benchmark tests of consistency evaluation to apply for the National Medical Products Administration's (NMPA) approval. The NMPA is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administr

Advertisement
Advertisement